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1. Introduction 
In the past decade, relevance and application of genomics and proteomics technologies in 
early detection of diseases have verified that numerous categories of diseases could be 
diagnosed at early stage which would be helpful in initiation of treatment. As a result of 
human genome studies, a shift has occurred from mRNAs to noncoding RNAs as a main 
regulator of human genome. The sequence analyses of genomes in eukaryotes indicated that 
simple unicellular organisms, invertebrates and mammals have approximately 25%, 80% 
and 98%, respectively, of their genomes composed of noncoding DNA regions [1]. In higher 
eukaryotic organisms, approximately, the entire genome is transcribed as  consisting of 
rRNA, tRNA, introns, 5' and 3' untranslated regions, and microRNAs. It also has been 
proposed that mammalian miRNAs are originated from transposons and repeats [2,3]. 
Moreover, it is showed that miRNAs could be developed from pseudogenes [4]. Exisisting 
analyses of the human genome reflects that the protein coding genes are low as 23500, 
indicating that a large segment of human genome consists of non-coding protein genes. 
Open reading Frames comprise less than 2%, repetitive sequences around 46% and non-
coding parts of protein-coding genes (introns, 5' and 3'-UTRs) around 25-27% of 3.2 billion 
bases in the human genome [5,6]. As the human genome and its functions are being 
explored, the roles of non-coding RNAs are becoming more evident in specific cellular 
functions. Members of non-coding RNAs include microRNAs and small nucleolar RNAs 
which are believed to have well preserved functions in various species. MiRNAs are 
functional molecules that have recently emerged as important regulators of gene expression 
at the posttranscriptional and translational levels. Endogenous miRNAs are involved in a 
variety of physiological and pathological processes in human. Target mRNA specification is 
defined by sequence complementarity between the seed sequence and the target mRNA. 
The technological advances and applications of functional RNA molecules for medicine 
provide important insights into molecular mechanisms affecting human health and disease 
and could eventually lead to the discovery of diagnostic biomarkers and the development of 
novel gene therapies [7].  
In this chapter, we first address the synthesis, mechanisms of action and functions of 
miRNAs. Then, we focus on recent advances and technologies in miRNA. Next, we discuss 
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the clinical applications of miRNA. At last, we review current knowledge of the roles of 
miRNAs in various diseases and determine the advantages and potential challenges of 
microRNA–based approaches compared to conventional drug-based therapies.  
2. MiRNA biology and function 
Micro ribonucleic acids (miRNAs) are a large class of endogenously expressed single 
stranded, evolutionarily conserved small non-coding RNAs, typically 17-25 ribonucleotides 
in length that are found in many plants, animals and DNA viruses  regulating gene 
expression in a sequence-dependent manner [8]. MiRNA has revealed the great potential 
regulating roles in various aspects of biological and pathological processes. They were first 
discovered in worms in 1993, Caenorhabditis elegans, lin-4, capable of modulating the protein 
expression of lin-14 opened up a new role for small RNAs in regulating gene expression [9]. 
While more than 3,000 miRNAs have now been identified in animals, plants and viruses, the 
human genome has been estimated to code up to 1000 miRNAs that are expected to regulate 
a third of all genes. A plethora of predicted mRNA targets, it is believed that these small 
RNAs have an enormous regulatory potentials [10,11]. In mammals, miRNAs derive from a 
large primary transcript, referred to as a pri-miR, transcribed by RNApolymerase II/III in 
nucleus. The pri-miR, which is likely hundreds to thousands of nucleotides long, 
experiences nuclear cleavage by a ribonuclease III called Drosha and the double-stranded 
DNA binding protein DGCR8/Pasha to generate a hairpin shaped ~70-nucleotide pre-
miRNA. Then, pre-miRNA is transported to the cytoplasm by the nuclear export factor 
exportin 5, and undergoes another processing where they serve as substrates of RNase Dicer 
and its  cofactors (PACT and TRBP) to generate ~22 nt miRNA duplexes. RNA duplex is 
unwound into a mature single-stranded miRNA, and loaded into RNA-induced silencing 
complex (RISC). Although most miRNAs in plants hybridize to target mRNAs with perfect 
complementarity, in animals the 5' proximal “seed” region (nucleotides 2 to 8) appears to be 
the primary determinant of the pairing specificity of the miRNA to the 3' untranslated 
region (3'-UTR) of a target mRNA. MiRNA then binds to complementary sites in the 3’-
untranslated region (3’-UTR) of target mRNA and regulate its expression either by causing 
degradation of mRNA or repression of their translation, depending on the degree of 
complementarity between the miRNA and its target [12-17]. Alternatively, pre-miRNAs are 
derived directly from size-matched introns. These are referred to as ‘mitrons’ skip the 
Drosha–DGCR8 processing step and are spliced out of their host genes. These lariats are 
debranched, refolded into the stem-loop structure of typical pre-miRNAs, and then enter the 
canonical pathway [18]. Of note, Drosha, DGCR8, and Dicer are the well-established 
regulators of miRNA processing. Defects in the miRNA biogenesis machinery could be 
intimately related to various diseases including cancer. 
3. MiRNA-mediated gene regulation 
The expression of miRNAs is vibrant depending on tissue types, metabolic status and 
disease condition. A potent trait of miRNA-based regulation is the capability of individual 
miRNAs to regulate multiple functionally related mRNAs, which itself regulates multiple 
metabolic genes [19,20]. Approximately half of all known miRNA genes are grouped in 
the genome and transcribed as polycistronic primary transcripts with the remainder 
expressed as individual transcripts from intergenic or intronic site. Regardless of genomic 
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organization, miRNAs function in a distinct yet cooperative manner to regulate cellular 
processes by coordinately targeting related proteins [21,22]. Furthermore, miRNAs often 
go to families of narrowly related or the same sequences. As of their homology in the seed 
sequence, the associated miRNAs are able to target the same mRNAs, which increases the 
effectiveness of repression. The number of validated mature human miRNA approaches 
over 1 thousand, with individual miRNAs capable to repress multiple genes. Of note, 
miRNAs have emerged as important regulators of every biological process involved with 
differentiation, cellular proliferation, tissue development and cell-type specific function 
and homeostasis. As a consequence, dysregulation of miRNAs have been implicated with 
impairment of regulatory networks. In fact, a multiple number of pathologies are 
associated with altered miRNAs expression [23].  It is becoming progressively more 
evident that the aberrant expression of miRNAs is causally related to a diversity of 
disease states. Stress-induced upregulation of miRNAs be able to result in the 
downregulation of a set of targeted mRNAs, whereas downregulation of miRNAs can 
lead to upregulation of target mRNAs. At last, it is the pattern of miRNA-induced gene 
expression that contributes to the consequential disease phenotype [24]. It was shown that 
diverse forms of stress alleviate mRNAs from miRNA repression by releasing mRNAs 
from P-bodies (cytoplasmic bodies containing mRNA degradation enzymes) and 
promotes their entry into polysomes, thereby enhancing translation of the preexisting 
mRNA [25]. Both changes in expression and function in response to stress increase their 
influence under conditions of disease states. The apparent roles of miRNAs in disease 
have led to an increasing interest in miRNA regulation as a therapeutic and diagnostic 
approach [26]. The role of miRNAs-mediated regulation in viral infection is becoming 
more evident. The outcome of miRNA repression is not well understood. Some reports 
showed that miRNA regulation led to translational inhibition, without affecting mRNA 
levels. Although there are accumulating reports that mRNA degradation is a consequence 
of miRNA regulation, it is unclear whether it is a consequence of translational repression 
or a separate pathway of miRNA regulation [27-30].    
4. MiRNAs expression profile analysis 
Investigating and implementing efficient tools for detection, quantification, and functional 
analysis of miRNAs is essential to explore the role of miRNAs signatures in health and 
disease process. Various studies exploited high throughput methods to analyze global 
miRNA expression in clinical samples. As a common platform, Oligonucleotide miRNA 
microarray analysis has been extensively used as high-throughput method for the 
evaluation of global expression levels in a large number of samples [31,32]. An original 
miRNA microarray platform by means of locked nucleic acid–modified capture probes has 
also been emerged. This procedure allows miRNAs with single nucleotide differences to be 
discriminated. Furthermore, MiRAGE, a form of serial analysis of gene expression to 
evaluate miRNA levels, and RAKE an RNA primed, array-based, Klenow enzyme high-
throughput assay, have also been built up to find out miRNA expression profiles [33,34]. Of 
note, the above-mentioned techniques were mainly developed to determine the cancer-
specific expression levels, however, the use of high-throughput arrays for investigating 
miRNA expression in non-neoplastic diseases is beginning to emerge. A number of miRNAs 
are up regulated in the brains of demised Alzheimer’s patients, implicating impairment of 
miRNA expression in neurodegenerative disorders [35]. A microarray-based approach has 
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also been used to profile miRNA expression in response to environmental stresses such as 
hypoxia. A method to weigh miRNA expression is the bead-based flow cytometric 
approach. Individual polystyrene beads coupled to miRNA complementary probes are 
marked with fluorescent tags. After hybridization with size-fractionated RNAs and 
streptavidin-phycoerythrin staining, the beads are analyzed using a flow-cytometer to 
measure bead color and phycoerythrin, demonstrating miRNA characteristics and loads 
respectively. The technique provides great specificity for intimately related miRNAs 
because hybridization happens in solution. [36]. Quantitative real-time polymerase chain 
reaction (qRT-PCR) have also been widely used to miRNA research due to its cost-
effectiveness, high throughput and higher detection [37]. Up to now, the most successful 
approach in terms of specificity and sensitivity is a two-step approach via looped miRNA-
specific reverse transcription primers and TaqMan probes. Multiplex PCR approaches for 
miRNAs have also been reported [38]. All of these technologies facilitating miRNAs 
expression profiling are essential for validation of microarray data. The high throughput 
capability of array-based platforms make them an attractive option for miRNA studies 
compared with lower throughput techniques such as Northern blotting and cloning. High-
throughput analysis of miRNA expression in various diseases only demonstrates that some 
miRNAs are over expressed while others are markedly reduced in other tissues. These are 
exclusively correlative data. In other words, high throughput platforms to gauge miRNA 
expression provide only correlative evidence that atypical miRNA processing. These 
techniques only convey us modest about the underlying miRNA expression problem. 
Besides, the threshold of differential miRNA expression required so as to impact biological 
processes is unknown for most disease-associated miRNAs. Of importance, the 
development of methods to manipulate miRNA expression has made possible examinaions 
into the cellular processes involved by differentially expressed miRNAs. 2-O-Methyl 
antisense single-strand oligonucleotides and locked nucleic acid–modified oligonucleotides 
have been developed as miRNA inhibitors, making the suppression of endogenous miRNA 
activity and its downstream effect on mRNA expression achievable [39-42]. The effect of 
target miRNA knockdown on cell morphology and function can be determined using 
standard assays for processes such as cell proliferation, migration, invasion, and 
angiogenesis. Cell-based assays that examine the role of miRNA in human disease are also 
recently emerged. Numerous studies in cancer cell lines, using either antisense inhibition or 
over expression of individual miRNAs, show a direct functional link between aberrant 
miRNA expression and an individual tumor [43-46]. It is well-known that cancer-based cell 
assays are suitable for biochemical experimentation. MiRNA mimicry, a complementary 
method to inhibition, newly used in vitro to identify cellular processes and phenotypic 
changes associated with specific miRNAs transfected into cell lines; which will be explained 
at the last section. Disruption in miRNA expression is not the only change that can modify 
the regulation of target mRNAs. Mutations in the 3′ UTR of the candidate disease genes that 
disrupt miRNA binding sites can also affect diseases through reduced or total loss of 
miRNA-mediated regulation.  
5. Biological functions of miRNAs 
While the "seed" region is most important for miRNA–mRNA interactions, applying this 
principle only leads to prediction of many miRNA targets that cannot be validated in vivo, 
raising the possibility that further imperative rules manage miRNA–mRNA interaction. A 
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prevailing aspect of all targets is that miRNAs usually target UTR sites that do not have a 
complex secondary structure and are located in accessible regions of the RNA. Since this 
model was proposed, several additional targets have been characterized in vivo, and 
approximately all are consistent with the proposed accessibility criteria [47,48]. MiRNAs are 
regulators of gene expression that control many biological processes in growth, 
development, differentiation, and metabolism. Their expression levels, small size, and mode 
of action pose unique challenges in studies elucidating the function of miRNAs. New 
technologies for identification, expression profiling and target gene validation will make 
easy the study of their involvement to biological processes and disease. Such information 
will be crucial to utilize the upcoming knowledge of miRNAs for the development of new 
human therapeutics. It is remarkable to think about whether individual miRNAs function 
separately on specific targets or if they can also function in a combinatorial manner. For 
instance, the effects of single miRNAs can be found in the regulation of lin-28 mRNA by lin-
4, the first known miRNA, discovered in 1993 and was shown to have significant functions 
in developmental timing of stage-specific cell lineages [49]. By contrast, many miRNA 
clusters inhabit in related introns of paralogous genes. These polycistronic miRNAs could be 
classified into the similar miRNA family based on sequence similarity in the miRNA 50 
region, implying that they might cooperatively control frequent sets of targets or molecular 
events. Besides to coordinately regulating a single mRNA, several members of a miRNA 
family can control sequential events [50]. Given the ability of miRNAs to regulate multiple 
genes, it will be interesting to examine whether they function through many of the same 
paradigms as transcription factors, such as combinatorial regulation and regulation of whole 
genetic programs. Genetic studies in Caenorhabditis elegans, Drosophila melanogaster have 
identified important functions of specific miRNAs in the coordination of cell proliferation 
and death during development, stress resistance, fat metabolism and brain morphogenesis 
[51,52]. For the past few years, one primary focus of the investigators studying mammalian 
miRNAs was to recognize and catalog the complete miRNA list and its expression pattern 
using cloning, bioinformatics and gene expression approaches. With these efforts nearing 
conclusion in the near future, the focus is shifting to the clarification of miRNA function. 
Several technological advances including bioinformatic prediction algorithms, reporter 
assays, in situ hybridizations, overexpression and silencing technologies, were developed to 
infer miRNA function. Here, we review the basic knowledge on miRNAs functions, 
especially highlighting recently discovered miRNA functions. The recent progress of 
miRNA involvements in organs development will be discussed. 
5.1 Pivotal functions of miRNAs in development and or differentiation 
Examining mice lacking the essential miRNA-processing enzyme Dicer is essential to 
investigate the role of miRNAs in development. Targeted deletion of Dicer in mice causes 
embryonic lethality before embryonic day (E) 7.5. Dicer-deficient embryonic stem (ES) cells 
are defective in differentiation both in vitro and in vivo, and do not form the three germ 
layers normally located in embryoid bodies derived from ES cells, suggesting an essential 
role for miRNAs in development [53]. In fact, without lin-4, C. elegans is unable to make the 
transition from the first to the second larval stage due to a differentiation defect, which is 
caused by a failure to posttranscriptionally repress the lin-14 gene, which is the target gene 
of lin-4 [54]. Similarly, without let-7, a failure of larval-to-adult transition was observed [55]. 
Therefore, miRNA function might be essential for ‘fine tuning’ developmental incidents 
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during the defined events of organogenesis. MiR-1–1 and miR-1–2 are rich in the developing 
heart. Enrichment of miR-1–1 is primarily observed in the atrial precursors before becoming 
omnipresent in the heart, whereas a miR-1–2 enhancer is particular for the ventricles in the 
developing heart; therefore, miR-1–1 and miR-1–2 might have chamber-specific effects in 
vivo [56]. MiR-1 in flies regulates the Notch signaling pathway by directly targeting mRNA 
of the Notch ligand, Delta, demonstrating that miR-1 functions to persuade differentiated 
cardiac cells from an equivalency group of progenitor cells [57,58]. MiRNAs regulate key 
events during neurogenesis in various species. In mammals, miR-134 is particularly 
expressed in the rat dendritic spine in hippocampal neurons. It binds to 3' UTR of Limk1 
and represses local LimK1 translation, which results in inhibition of dendriticspine growth. 
Stimuli such as brain-derived neurotrophic factor can mitigate this suppression. This finding 
revealed that miRNAs can be key regulators of neuronal structure and plasticity [59]. 
MiRNAs control key events during neurogenesis. In zebrafish, maternal zygotic Dicer 
mutant embryos have severe defects in the development of the neurocoel and the neural 
tube. These developmental defects are saved by members of the miR-430 family, indicating 
that the latter are the major miRNAs involved in the neurogenic defects [60]. MiRNAs can 
also be important regulators of neuronal structure and plasticity in mammals [61]. A 
discrete set of miRNAs is exclusively expressed in pluripotent embryonic stem cells but not 
in differentiated embryoid bodies, suggesting a role in stem cell self-renewal [62]. 
Understanding how miRNAs are processed and how they are integrated into the complex 
regulatory networks that direct the developmental, homeostatic and physiological processes 
of organisms are extremely crucial. 
5.2 Cell proliferation and apoptosis 
MiRNAs have been shown to regulate main genes for cancer progression that coordinately 
manages cell proliferation and apoptosis. MiRNAs regulate pathways controlled by genes 
such as p53, MYC and RAS. Moreover, miR17-92 cluster was shown to be competent to 
operate as a functional switch between cell proliferation and apoptosis. The fly miRNA, 
Bantam, was originally characterized from a fly P-ELEMENT screen for genes that promote 
cell proliferation and suppress apoptosis during tissue growth [63]. Its sequence 
complementarity with the 3' UTR and its functional antagonism of the pro-apoptotic hid 
gene were the first clues for the translational repression of hid by Bantam [63, 64]. In 
addition, fly miR-14 was recognized through a P-element screen for inhibitors of apoptotic 
cell death. Deficiency in miR-14 enhances cell death that is induced by the cell death 
activator, Reaper, and results in defective stress responses and fat metabolism. Loss of miR-
14 also leads to an elevated level of Drice, an apoptotic effector caspase, indicating a direct 
or indirect repression of Drice by miR-14 [65]. 
5.3 Contribution to maintain tissue identity 
Yu et al. conducted a genome-wide analysis of the expression profiles of miRNA targets in 
human, mouse and Drosophila. They found that the expression levels of miRNA targets are 
significantly lower in all mouse mature tissues and Drosophila later life stages than in the 
embryos. These results point out that miRNAs may play roles in determining the timing of 
tissue differentiation during the larva period of Drosophila development and maintaining the 
tissue identity during adulthood [66]. 
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5.4 As regulators for noise filtering and buffering 
Eukaryotic cells are noisy milieus in which transcription often happens in a bursting 
manner, causing the number of mRNAs per cell to swing significantly [67]. In positive 
regulatory loops, noise or stochastic fluctuations of gene transcripts and protein molecules 
leads to randomly switching cell phenotypes in yeast, while a negative regulator adding in 
the positive regulatory loops often helps in reducing such noise in biological systems and 
making a strong result for cell development. Because miRNAs can adjust target protein 
levels more rapidly at the posttranscriptional level, they may significantly shorten the 
response delay and, in turn, provide more effective noise buffering. The miRNA miR-17 
might play a role in preventing noise-driven transition from apoptosis to cell proliferation. It 
is possible that miRNAs serve to buffer stochastically fluctuating expression of genes in 
positive regulatory loop. MiRNAs provide a common mechanism in buffering gene 
expression noise by frequently regulating positive regulatory loops [68,69]. 
Up to date, miRNAs have been shown to be involved in a range of cellular processes 
primarily developmental and metabolic processes including: cell proliferation, cell 
differentiation, developmental timing, fat metabolism, apoptosis, insulin secretion, stem cell 
maintenance, neuronal patterning, and haematopoietic lineage differentiation. Table 1 lists a 
number of the main important miRNAs that are associated with defined biological processes 
and some of the target genes through which they exert their regulatory function. 
6. MiRNAs- associated disease mechanisms  
MiRNAs- Associated Disease Mechanisms are quietly abundant so as because of time and 
place limitations, it is impossible to discuss in detail the all respective involved mechanisms. 
We then describe the essentials and needful accordingly. The high sequence conservation of 
many miRNAs among faintly related organisms suggests strong evolutionary pressure and 
involvement in main physiological processes by miRNAs. In fact, miRNA deficiencies or 
excesses are correlated with a range of clinically imperative diseases including myocardial 
infarction, virus infection, Alzheimer's disease, metabolic diseases, cancers, and many others 
[70-73]. Calin and colleagues found that a region containing miR-15 and miR-16 at 
chromosome 13q14 was commonly deleted in the majority of chronic lymphocytic leukemia 
cases [74]. It is quite clear that many miRNAs are associated with primary human tumors, 
and more than 50% of human miRNAs genes are located at genomic regions implicated in 
cancers, such as common breakpoint regions and fragile sites [75,76]. Discovery of the role 
of miRNAs in various pathological processes has shed light to the possible applications of 
miRNA in molecular diagnostics and prognostics, particularly for cancer. It is obvious that 
miRNAs in deleted or amplified regions in cancer samples contain altered expression levels. 
The impaired expression of various miRNAs throughout oncogenesis may advance or 
impede the tumor formation by modulating the expression of critical genes involved in 
cancer cell proliferation or survival. Though the vast majority of associations between 
miRNAs and human disease are coupled with tumorigenesis, there is accumulating 
evidence that miRNAs most probably are involved in multiple diseases. An investigation 
has added indirect support that miRNA changes are causal, rather than consequential, of 
cellular transformation [77]. One of them is fragile X mental retardation (FXMR) caused by 
absence or mutation of the fragile X mental retardation protein. Experimental results from 
Drosophila melanogaster indicate that FXMR may be a part of RISC [78]. The syndrome most 
often results from trinucleotide expansion of the CGG repeat in the 5′ UTR of the FMR1 
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Abbreviations: HAND2, hand transcription factor; HDAC4, histone deacetylase 4; CYP1B1, cytochrome 
P450 1B1; PFV1, primate foamy virus type 1; P50GAP (RICS), Rho GTPase-activating protein; ERK5, 
extracellular signal regulated kinase 5; AT1 R, angiotensin II type 1 receptor; c-KIT, stem cell factor 
receptor; HOXB8, homeobox B8; TRAF6, TNF receptor-associated factor 6;nPTB, neuronal 
polypyrimidine tract-binding protein;SRF, serum response factor; LIMK1, Lim domain containing 
protein kinase 1; MTPN, myotrophin; Hoxb8, homeobox B8; rld1, rolled leaf1; MAFB, v-maf 
musculoaponeurotic fibrosarcoma oncogene homologue B; BCL2, B-cell lymphoma 2; IRAK1, IL-1 
receptor associated kinase; 
Table 1. MicroRNAs associated with experimentally defined functions and targets. 
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gene, causing hypermethylation and defeat of FMR1 expression [79]. Biochemical studies 
using recombinant FMRP and FXR1P suggest that FMR1P, FXR1P, and FXR2P proteins 
perform as acceptor molecules for Dicer-processed miRNAs and help direct gathering of 
miRNA [80]. The dAGO1 is indispensable for miRNA-directed gene silencing in Drosophila, 
showing a functional interaction with dFMR1, strengthens the dispute that failing in 
miRNA-mediated translation repression during neural development could result into fragile 
X syndrome [81,82]. It has been shown that expression of many miRNAs is altered in heart 
disease and that various types of heart disease are associated with discrete alterations in 
miRNA expression [83]. Such changes intimately look like the miRNA expression patterns 
observed in fetal cardiac tissue, indicating a novel mode of regulation for the transcriptional 
changes in cardiac failure. Numerous miRNAs were found to be dysregulated in two mouse 
models of cardiac hypertrophy. MiR-9 and miR-128a were overexpressed in the brains of 
Alzheimer’s patients and 16 miRNAs were differentially expressed in the brains of 
schizophrenics. A mutation in the 3' UTR of the SLITRK1 gene that is associated with 
Tourette’s syndrome led to enhanced repression by miR-189 [84-87]. Several hundreds of 
miRNAs were identified in human but currently, only a couple of specific targets have been 
experimentally validated. As predicted by bioinformatical analysis, a single miRNA can 
potentially target different mRNAs.  
MiRNA regulation has also been implicated in virus-induced diseases. In fact, cellular 
miRNA expression may confer host immunity against viral infections; whereas viruses may 
have evolved to utilize miRNA machinery for their replication. It was observed that 
production of miRNAs by RNA viruses or cytoplasmic DNA viruses is unlikely, due to the 
compartmentalization of miRNA processing in the nucleus, as well as the fact that Drosha 
processing of miRNAs from RNA viruses would result in cleavage of the viral genome [88]. 
Increasing evidence suggests that viruses interact with the miRNA machinery [89]. Host 
miRNAs can also be used for viral replication as well as antiviral defense. The small size of 
miRNA precursors makes them also potentially ideal for use by oncogenic viruses as 
inhibitors of host cell defense pathways. For example, Human Papilloma Virus 16 (HPV16), 
is associated with cervical cancer, incorporates into miRNA genes at a rate 3 times higher 
than to the rest of the genome [90]. In fact, Cellular microRNAs have regulatory functions 
and direct antiviral consequences. A cellular microRNA effectively restricts the 
accumulation of the retrovirus primate foamy virus type 1 (PFV-1) in human cells. Viral Tas 
protein suppresses microRNA-directed functions in mammalian cells and displays cross-
kingdom antisilencing activities [91]. Epstein-Barr virus (EBV) is a large DNA virus that 
preferentially infects human B cells and expresses a number of microRNA genes. The small 
RNA profile of cells infected by EBV was recorded and discovered that EBV miRNAs 
originated from five different double-stranded RNA precursors clustered in two regions of 
the EBV genome. Epstein-Barr virus use RNA silencing as a method for gene regulation of 
host and viral genes in a non-immunogenic manner [92]. Nearly and likely more, 11 viruses 
have been shown to encode their own miRNAs. These viral miRNAs stand for potential 
antiviral targets and might also serve as diagnostic markers for viral infection or stage of 
infection. Viruses use miRNAs in various ways, such as to inhibit viral or host transcripts or 
to recruit host miRNAs for viral replication. 
7. MiRNAs and cancer 
The aberrant expression of miRNA in cancers and the fact that approximately half of 
miRNA genes are localized in cancer-associated genomic regions or in fragile sites indicates 
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the potential role of miRNAs as oncogenes or tumor suppressor genes in human 
carcinogenesis. MiRNA acts as oncomiRNA or tumor suppressors to affect the 
tumorigenesis if their target mRNAs were encoded by tumor suppressor genes or 
ontogenesis. MiRNAs still mainly intact in conventionally collected, formalin-fixed and 
paraffin-embedded tissues and even a modest number of miRNAs are adequate to 
discriminate human tumors according to the developmental lineage and differentiation state 
of the tumors [93-95]. The first association between miRNAs and cancer was identified by 
Croce and colleagues when the miR-15a-16-1cluster was implicated as a putative tumor 
suppressor gene mapping to chr 13q14, a small genomic region frequently deleted or 
translocated in chronic lymphocytic leukemia [96]. Since the predicted number of miRNAs 
in the human genome is as many as 1000. Regulation mediated by these genes has possibly a 
great impact on gene expression because, based on computional predictions, a single 
miRNA can target dozens of genes. Each cancer tissue has a particular miRNA signature 
and miRNA based cancer sorting is a very effective and potential tool. A subset of cancer-
related miRNAs are persistently involved in a variety of cancers so that the miR-17-92, miR-
106b-25 and miR-221-222 clusters, miR-155, let-7, miR-34a, miR-200 and others were 
revealed to play key roles in a variety of oncogenic processes [97,98]. Other miRNAs are 
expressed only in tumors of a limited tissue type and may be the most precise approach of 
defining not only the cell of origin, though the state of differentiation of a tumor. Moreover, 
miRNA signatures specify tumor subtypes and can help envisage prognosis and reaction to 
therapy. It is likely that numerous further essential oncomir-regulated targets/pathways 
with additional oncomirs will persist to be described in this fast-moving field [99,100]. To 
initiate and maintain a tumor, cancer cells must obtain the ability to proliferate 
autonomously, elude apoptosis and self-renew. To expand progress and metastasize, solid 
tumors also require stimulating angiogenesis, attacking normal tissue boundaries and 
becoming motile. Cancer-related miRNAs are implicated in each of these steps. For example, 
miR-15a-16 expression is downregulated in nearly all cases of CLL and prostate cancer; 
while miR-25/92 are upregulated in the majority human cancers. MiR-34a, which is 
transactivated by p53, one of the main tumor suppressor genes recurrently inactivated in 
human tumors, operates as a tumor suppressor miRNA by inducing cell cycle arrest and 
apoptosis in breast and lung cancer cells. This miRNA inhibits the expression of cyclin D1 
and the cyclin-dependent kinase CDK6, which force cell cycle progression from G1 to S 
phase, as well as SIRT1, suppresses p53 transcriptional activity and the expression of its 
targets p21 and PUMA [101-103]. MiRNAs also play a main role in regulating cancer cell 
self-renewal. A self-renewing pool of immature cancer cells within a tumor, are thought to 
serve as a self-renewing reserve to generate new cancer cells. These cells are also relatively 
resistant to chemotherapy and radiotherapy and likely play a major role in tumor recurrence 
after therapy. The let-7 family of miRNAs, which is not expressed in CSC (or other types of 
normal stem cells), acts as a master regulator of self-renewal in breast CSC. Processing of the 
let-7 primary transcripts to the mature miRNA is inhibited at several steps by lin28, which is 
only expressed in stem cells [104-106]. Invasion of contiguous tissue and metastasis by 
epithelial cancer cells is another key step in tumor progression and is thought to involve a 
process termed epithelial mesenchymal transition. Epithelial cancer cells at the periphery of 
the tumor employ in a complex crosstalk with stromal cells leading to a global re-
programming of gene expression with loss of epithelial traits and acquisition of 
mesenchymal properties, including invasion and motility [107]. Tumor-associated miRNAs 
along with validated target genes are presented in Table 2.  
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miRNAs Cancer Expression Targets 
miR-21 
Breast, Colon, Lung, 
Pancreas, Brain, 
Liver 
Up 
CDK6, PDCD4, 
FAS, IL6R TPM1, 
CDKN1A, SOCS5 
miR-25/92 
Leukemia, Lung, 
Stomach, Colon, 
Prostate, Thyroid 
Up CDKN1C, BCL2L11 
miR-142  
Aggressive B cell 
leukemia 
Up 
Translocated c-MYC 
gene 
miR-155  
Chronic 
lymphocytic 
leukemia 
Up BIC RNA 
miR-186 
Chronic 
lymphocytic 
leukemia 
Up IgVh gene 
miR-221  
Thyroid, Stomach, 
Pancreas, Prostate, 
Melanoma 
Up 
CDK1B, CDKN1C, 
KIT 
Let-7 Breast, Lung Down 
LIN28, HMGA2, 
kRAS, NF2 
miR-335  Breast Down SOX4, MERTK 
miR-372/3 
Breast, Testicular 
germ cells 
Down LATS2, CD44, CD24 
miR-15/16 
Chronic 
lymphocytic 
leukemia 
Down 
BCL2, PDCD4, JUN, 
MCL1,RAB21, 
PRIM1 
miR-17/20/93/106 
Lung, Stomach, 
Colon, Pancreas, 
Prostate, Leukemia, 
Thyroid 
Up 
E2F1, CDKN1A, 
RUNX1, NCOA3 
Table 2. Tumor-associated miRNAs along with validated target genes.  
Overall, it is proposed that miRNAs may regulate tumorigenesis through a overabundance 
of possible oncogenic mechanisms. Genomic deletion or epigenetic silencing of a miRNA 
that normally represses expression of one or more oncogenes might lead to increased 
oncogenic expression. Alternatively, amplification, overexpression, or loss of epigenetic 
silencing of a gene encoding an miRNA that targets one or more tumor suppressor genes 
could inhibit the activity of an anti-oncogenic pathway [108]. Besides, mutations affecting 
the sequence of the mature miRNA or target mRNA could modify binding of the miRNA to 
its related targets leading to alterations in the balance of critical growth regulatory proteins 
[109]. The onco-microRNA expression profiling of human malignancies has also identified 
several diagnostic and prognostic cancer signatures. Furthermore, some miRNAs are 
downregulated in cancer, such as let-7 and miR-34a. The widespread differential expression 
of miRNA genes between malignant and normal cells is a complex phenomenon and may 
engage multiple mechanisms, including miRNA transcriptional control by tumour 
suppressor genes, oncogenes, epigenetic mechanisms and genomic abnormalities [109,110]. 
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Moreover, germ-line and somatic mutations in miRNAs or polymorphisms in the mRNAs 
targeted by miRNAs may also participate to cancer predisposition and progression. It has 
been suggested that alterations in miRNA genes play a serious role in the pathophysiology 
of many human cancers [111]. 
7.1 MiRNAs and esophageal carcinoma 
MiRNA plays role as oncomiRNA or tumor suppressors to influence the tumorigenesis if 
their target mRNAs were encoded by tumor suppressor genes or ontogenesis. Aberrant 
miRNA expression has been identified and confirmed in esophageal carcinoma. MiRNAs 
expression profiling differs markedly between esophageal squamous cell carcinoma and 
esophageal adenocarcima, indicates that these two main forms of esophageal carcinoma 
have distinct etiologic and pathologic characteristics. The miRNAs which are highly 
expressed in tumor can work as tumor promoter by targeting and inhibiting diverse tumor 
suppressor genes that itself were involved in carcinogenesis of esophagus [112-114]. Apart 
from identifying different cancer-related miRNAs, efforts were made to recognize their 
target genes, messenger RNAs and receptors, which will result into their contribution in 
cancer treatment. For example, one of the putatively identified targets of miR-21 is PTEN 
[115]. A decrease in functional PTEN causes constitutive activation of downstream 
components of the PI3K/AKT pathway, leading to tumor progression and metastasis. Thus, 
down-regulation of PTEN by miR-21 may contribute to transformation and increased tumor 
cell survival [116]. Epigenetic silencing of tumor suppressor genes is an additional 
mechanism of cancer development. In fact, the expression of tumor suppressor being able to 
get altered in epigenetic silencing mechanism via expression of miRNA. It was found that 
miR-127, located in a CpG island, identified in hematological cancers and deleted by loss of 
heterozygosity in solid tumors [117]. Further investigation is required for improved 
thoughtful their role in carcinogenesis of esophageal carcinoma and for better application in 
the future. 
7.2 MiRNAs and breast cancer 
MiR-10b, miR-125b and miR-145, are down-regulated and miR-21, miR-155, get up-regulated 
in breast cancer. MiR-125b gene is located at chromosome 11q23-24, one of the regions most 
frequently deleted in breast, ovarian, and lung tumors [118, 119]. MiR-145 was progressively 
down-regulated from normal breast tissue to cancer with high proliferation index. The 
expression of various let-7 miRNAs was down-regulated in breast cancer samples with 
either lymph node metastasis or higher proliferation index [120]. It was found that 
upregulation of miR-10b commences breast cancer invasion and metastasis [121]. The 
justification for using miRNAs as potential therapeutic targets is underlined by the fact that 
miRNA overexpression in cancer cells has a pathogenic effect. 
7.3 MiRNAs and lung cancer 
let-7 expression is recurrently reduced in lung cancers and associated with decreased post 
operative survival [122, 123].  It was shown that miR-155 was over-expression, while miR-17-
92 cluster was over-expressed [124]. An in vitro experiment has revealed that overexpression 
of let-7 results in the inhibition of lung cancer cell growth. Furthermore, Dicer protein 
expression is reduced in a fraction of lung cancers with a prognostic impact on the survival 
of surgically treated patients [125]. 
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7.4 MiRNAs and hematological malignancies 
It was shown that two miRNA genes located at 13q14.3 within a 30-kb region of minimal 
loss in. Both of these genes, miR-15a and miR-16-1, are down-regulated in more than 60% of 
CLL cases. Cluster miR-15b, miR-16-2, along with a different promoter, was found on 
chromosome 3q25–26.169. These miRNAs are less intensively expressed in normal cells; 
however, they may play a role in cases of 13q14 deletions [126,127]. It was also found that 
down-regulation of miR-16-1 and miR-15a expression correlates with allelic loss at 13q14, 
could be essential for clinical classification of CLL. Patients with a normal karyotype or 
deletion of 13q14 as the sole genetic abnormality have a better prognosis than those with a 
complex karyotype [128,129]. Indeed, the miRNA expression profile is associated with 
progression in CLL and be able to serve as a potential prognostic marker. As the 
investigation on lymphoma showed an elevation in the amount of miR-155/ BIC RNA 
happening in lymphomas derived from B cells, therefore miR-155 possibly will play a role in 
the pathogenesis of B cell lymphomas [130]. MiR-142 located at a spot of rearrangement 
linked to human leukemia that causes an aggressive B cell leukemia due to up-regulation of 
a translocated c-MYC gene. Moreover, it was revealed that miR-142 expression is higher in 
B-lymphoid and myeloid lineages compared to other hematopoetic tissues [131, 132]. 
7.5 MiRNAs and brain tumors 
Microarray studies of glioma tissue have demonstrated a number of miRNAs implicated in 
glioma formation and propagation. MiR-7, -10b, -15b, -21, -26a, -124, -128, -137, -181a, -181b, 
-221, -451, play a role in human glioma. The majority of miRNAs are underexpressed in 
proliferating glioma cells with the important exception of miR-10b, -21, and -221 [133]. 
MicroRNAs regulate oncogenes implicated in brain tumor formation. Interestingly, 
microRNAs may also dictate the invasiveness and aggressiveness of tumors. MicroRNAs 
are significant regulators of cellular proliferation and differentiation so that it was found 
that miR-124 and miR-137 are downregulated [134]. On the other hand, microRNAs have 
been shown to work as tumor suppressors where downregulation of miR-181a and miR-
181b involved in glioma formation was reported suggesting a tumor suppressor role for 
miRNAs [135]. Evidence for a role of miRNA in brain tumorigenesis recently emerged via 
the involvement of miRNA in medulloblastoma by demonstrating that miR- 124 modulates 
cell-cycle regulation in medulloblastoma cells. They showed that miR-124 expression is 
significantly decreased in medulloblastoma [136]. Therefore, strong evidence raising that 
miRNAs are integrally involved in brain tumor development and progression was proven. 
The discovery of the role miRNAs in brain tumors has also revealed a new category of 
therapeutic targets. 
7.6 MiRNAs and cardiovascular diseases 
MiRNAs are fundamental for heart development and regulating the expression of genes 
which play a part in cardiac function including the conductance of electrical signals, heart 
muscle contraction, and heart growth and morphogenesis. The most abundant miRNAs in 
heart are miR-1, let-7, miR-133, miR-126-3p, miR-143, miR-30c, and miR-22 [136]. It was 
found that loss-of-function of miR-1 prevented heart arrhythmia, whereas miR-1 
overexpression led to heart arrhythmia in normal and infarcted hearts. The same also 
showed that both gain- and loss-of function of miR-1 affect conductivity through affecting 
potassium channels [137]. MiR-1, miR-133 and miR-208 are considered muscle specific, 
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being primarily expressed in cardiac and skeletal muscles and also the intronic miRNAs 
including miR-208a, miR-208b, and miR-499 control muscle performance [138-140]. 
MiRNA expression profiles in a given tissue are dependent on the disease state. In order to 
adjust to the workload and impaired cardiac function, the heart may react by undergoing 
large cardiac remodeling known as cardiac hypertrophy. Invstigators established an 
association between miRNAs and hypertrophy by demonstrating that stress regulated 
miRNAs could activate both positive and negative persuade on the hypertrophic growth 
response [141,142]. Investigation on three various types of failing hearts showed that around 
50% of miRNA were differentially expressed in at least one disease group, while seven 
miRNAs revealed similar regulation in all three disease states [143]. Another study revealed 
that a large fraction of miRNAs were either up- or down regulated in the same direction in 
fetal and failing heart compared with normal heart [144]. Changes in miRNA expression 
profiles in experimental models may also provide further insights into our understanding of 
heart failure.  Arrhythmias arise due to heart disease or mutation in ion channel genes, 
however, miRNAs, such as miR-1 and miR-133 have been implicated to function in cardiac 
conduction system. The involvement of miR-1 in cardiac conductance was further confirmed 
by over expression studies in normal and infarcted rat hearts so as upregulation of miR-1 in 
individuals with coronary heart disease [145,146].  
Myocardial vascularization subsequent MI needs signaling by angiogenic growth factors, 
such as vascular endothelial growth factor and fibroblast growth factor. MiR-126 is an 
endothelial cell–specific miRNA that plays an critical role in neoangiogenesis following 
MI and in maintenance of vascular integrity. The actions of miR-126 reflect its potentiation 
of mitogen-activated protein kinase signaling downstream of VEGF and FGF. Spred-1, an 
intracellular inhibitor of the Ras/mitogen-activated protein kinase pathway, serves as a 
key target for repression by miR-126. These findings suggest that strategies to raise miR-
126 expression in the ischemic myocardium could enhance cardiac repair [147,148].  For 
the first time, it was showed that aberrant expression of miRNAs in the vascular walls 
after carotid artery balloon angioplasty in rats. This team identified p27 (Kip1) and p57 
(Kip2) as potential targets for these miRNAs in these cells. Further by knocking down 
miR-221 and miR-222 in rat carotid arteries, they revealed therapeutic potential for these 
miRNAs in suppressing cell proliferation in vivo and neointimal lesion formation after 
angioplasty [149, 150]. 
The role of miRNAs in regulating endothelial cells in response to hypoxia was also studied 
[151]. They observed miR-210 upregulation in human endothelial cells in response to 
hypoxia affecting cell survival, migration, and differentiation. MiR-210 overexpression in 
normoxic endothelial cells stimulated angiogenesis whereas the opposite was observed with 
miR-210 blockade. Furthermore, a Dicer knockdown approach was used to examine the 
implication of miRNA in regulating the redox state and angiogenic response of human 
microvascular endothelial cells. The reduced miRNA levels induced expression of the 
transcription factor HBP1 that negatively regulates expression of p47phox of the NADPH 
oxidase complex. This study provides the first evidence that redox signaling in cells is 
subjected to regulation by miRNA [152].  
Taken together, it seems clear that miRNAs have a central role in regulating gene expression 
in the heart. These studies indicate that miRNAs are important during heart development 
and adult cardiac physiology, and modulate a diverse spectrum of cardiovascular functions 
in vivo. Furthermore, these studies also have implications for understanding complex 
pathways, e.g., interactions between miRNAs, cell signaling and transcription factors, 
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involved in heart diseases and can lead to potential opportunities in manipulating miRNAs 
as therapeutic targets. 
8. Diagnostic and prognostic value of miRNA: as novel promising biomarkers 
Make use of blood biomarkers was proved to be a reasonable means for early detection of 
some diseases. Since abnormal miRNA expression seems to characterize many diseases, 
increasing evidence indicates that the specific miRNA expression can be applied not only for 
diagnosis but also for classification of different tumors. The distinctive expression profile of 
miRNAs in different types and at different stages of cancer, and in other diseases, suggest 
that miRNA can be exploited as novel biomarkers for disease diagnostics and might present 
a new strategy for miRNA gene therapy. At the same time, risk stratification and prognosis 
assessment have become a major concern in the era of personalised medicine. Although, 
gene expression profiling has reached a plateau in this regard, recent miRNA studies 
illustrate great promise whereas aberrant miRNA profiling and or abnormal miRNA levels 
in tissues or in plasma can perform as a robust predictor of overall survival and disease 
outcome in various disorders. Because numerous miRNAs are expressed in a tissue-specific 
manner and their levels in different organs vary in association with disease states, these 
small molecules represent an attractive new class of highly specific biomarkers [153-157]. 
Some reports have previously illustrated the potential of these small RNA molecules as 
biomarkers in cancerous patients [158]. Moreover, serum of patients with autoimmune 
disorders exhibits increased amounts of certain miRNAs. Another study showed that miR-
155 and miR-146a are raised in samples from patients with rheumatoid arthritis [159]. One 
report revealed that the miRNA profile in the serum of type 2 diabetic patients is 
considerably different from those of healthy 
individuals and includes three miRNAs that were not associated with other disorders [160-
162]. Recent evidence revealed that profile of miRNAs expression correlated with 
clinicopathological attributes and disease consequence. Because abundant studies 
demonstrated that miRNAs are implicated in cancer development and metastasis, miRNAs 
have great cancer diagnostic and prognostic potentials. Several miRNAs was showed to be 
associated with prognostic factors and disease progression in chronic lymphocytic leukemia 
[163]. Furthermore, high expression of miR-155 and low expression of let-7a-2 were 
associated with poor prognosis in human lung cancer [164]. For instance, a number of 
studies demonstrated that MicroRNA profiling acts as a tool to understand prognosis, and 
manage therapy response and resistance in breast cancer [165-167]. They revealed that 
expression level of miR-210 in early initiation of the disease was associated negatively with 
overall survival, suggesting that miR-210 could be free prognostic factor for breast cancer. 
MiRNA microarray profiling in breast cancer was also shown a positive correlation with 
epidemiological and pathological features of the disease so that miR-21 was associated with 
pathological features including advanced tumor stage, lymph node metastasis, and poor 
survival [168]. Taken together, in cancerous conditions, microRNAs expression profiling is 
certainly considered widely as a novel prognostic and diagnostic tool in clinical setting 
compared to mRNA; because, firstly that miRNAs stability in paraffin-embedded tissues is 
higher and remain primarily intact in plasma/serum compared with mRNA, due to lack of 
endogenous RNase activity.  Secondly, a small number of miRNAs likely is adequate to 
distinguish cancers from normal [169,170]. These findings suggest that miRNA profiling is 
far more informative than usual mRNA profiling. Furthermore, predictive miRNA 
www.intechopen.com
 Gene Therapy - Developments and Future Perspectives 
 
108 
expression signatures may be identified within tumor groups that predict the rate of 
progression risk, survival or existence of metastases. Lastly, miRNAs could be a target or 
tool for cancer prevention or therapeutic intervention. Hence, with mounting facts 
concerning miRNAs associated with molecular signatures and clinicopathological 
characteristics of various disorders, it is deemed that miRNAs may verify useful as 
diagnostic and prognostic means in the future. 
9. MiRNA–based therapeutics 
MiRNAs have great potential to be developed as a novel class of therapeutic targets. The 
exclusive biogenesis and mechanism of miRNA action allocate it to be free from the 
problems including off-target effects and drawbacks of siRNA which greatly hamper 
therapeutic use of siRNA. The benefit on specificity and toxicity, and the striking feature of 
multiple targeting potential, miRNA will also become an excellent tool for gene 
intervention. It is well known that miRNA levels are either upregulated or downregulated 
in various diseases. Therefore, miRNAs need to be finely modulated so as to either 
knockdown pathogenic or aberrantly expressed miRNAs or induce expression of optimistic 
miRNAs to threshold levels. There are several approaches to attain these in vivo and in vitro. 
In cancer therapy, reasonable approaches for therapy would comprise achieving “gain” or 
“loss” of miRNA roles in the cancer cells. Because many miRNAs have been identified to 
impart tumor suppressive effects, restoring their expression could produce therapeutic 
effects. It was found that ectopic overexpression of let-7 tumor suppressor miRNA inhibited 
the growth of lung, liver and pancreatic cancer cells. Moreover, systemic administration of 
miR-26a using adeno-associated virus in an animal model of hepatocellular carcinoma 
inhibited tumor progression. These findings demonstrated an important target miRNA with 
tumor suppressive activity and signified that adenoviral vector-based delivery might be a 
clinically viable approach [171,172]. Besides, synthetic miRNA mimics have also been 
introduced to re-establish miRNA function within the tumor. In case of oncogenic miRNAs, 
a number of approaches have been designed and tested to attain their downregulation [173]. 
For oncogenic miRNAs, multiple approaches have been designed and tested to achieve their 
downregulation. These approaches include the use of anti-miRNA oligonucleotides 
(AMOs), small molecule inhibitors, miRNA sponges and miRNA masking. Of note, 
downregulation of miRNAs could be approached via its biogenesis. In a one investigation, 
several small organic molecules were screened to block miR-21 function and azobenzene 
was identified as an efficient inhibitor of miR-21 expression [174]. An additional approach is 
the application of synthetic mRNA consisting multiple pairing sites for endogenous miRNA 
[175]. These synthetic mRNAs, known as miRNA sponges, act by sucking up the target 
miRNAs and blocking their regulatory function in the cell [176]. 
Taken together, to date, two strategies have been introduced to exploit miRNAs as a novel 
and effective therapeutic tool. These include inhibition strategy and replacement strategy. 
Antisense inhibition of mature miRNA is one the inhibition strategies. Antisense miRNA 
Oligonucleotides (ASOs) are currently the most easily approachable technology for 
inhibiting miRNAs therapeutically. Anti-miRNA ASOs (AMOs) have been used by many 
groups to inhibit miRNA activity in cell culture. A group of investigators demonstrated that 
oligonucleotides carrying 2′sugar modifications (including 2′- (2′-F) and locked nucleic acid 
(LNA) plus phosphorothioate backbone modification, most probably works as successful 
inhibitors of miRNAs in cell culture [177–180]. It seems that there are other factors vital for 
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effective miRNA targeting, which will be imperative to appreciate to develop the most 
compelling AMOs for therapeutics. The most likely AMO binding site is the RISC-loaded 
miRNA, and there is indirect proof to support that. How this results in degradation is not 
clear, it may engage accelerated turnover of the miRNA complex [181]. Further approaches 
for modulating or improving oligonucleotide distribution in vivo include liposomal 
formulation and conjugation chemistry. Some progress has been made in liposomal delivery 
of ASOs [182,183]. However, route of administration, toxicity, and the cost made limited 
employing of oligonucleotide/liposome complex in practice. These limitations are needed to 
be addressed effectively in order to develop from a laboratory implement to a commercially 
practical therapeutic and clinical setting [184,185]. An alternative approach to targeting 
miRNAs therapeutically is by inhibiting its processing. This could be achieved by inhibiting 
Drosha, Dicer, or other miRNA pathway components, which could access by small molecule 
drugs. The anticipated pleiotropic effects of this approach may be challenging. On the other 
hand, an oligonucleotide complementary to an individual pri-miRNA designed to interrupt 
the hairpin structure could prevent Drosha recognition or processing [186,187]. It could also 
be potential to target pri-miRNAs with ASOs that function by an RNase H mechanism. One 
team showed inhibition of a pre-miRNA hairpin in the cytoplasm with a siRNA targeted to 
the loop region, requiring much higher doses of siRNA than a typical mRNA target [188]. 
The next effective approach is replacement strategy.  One approach to achieve this is 
through the introduction of a double-stranded miRNA mimetic, corresponding to the 
endogenous Dicer product and analogous in structure to a siRNA. This approach will likely 
face all the same impediments that siRNA therapeutics currently encounter, mainly the 
trouble of systemic delivery to tissues. Nucleotide modifications to improve stability to 
nuclease degradation and avoid quick renal clearance of the dsRNA from the blood were 
widely investigated, and a general understanding of what kinds of modifications are 
beneficial [189- 191]. The current progress in therapeutic delivery of siRNA indicates that 
augmentation of miRNA function with dsRNA mimetics will ultimately be promising.  
A substitute strategy for therapeutic miRNA replacement is a gene therapy approach. This 
involves expression of a short hairpin RNA (shRNA) from a polymerase II or III promoter, 
in a DNA or viral vector that is subsequently processed by Dicer prior to loading into RISC. 
Benefits to this approach are the potential for more persistent silencing compared to double-
stranded siRNA or miRNA mimetics, plus the simplicity of expressing several miRNAs 
from one transcript. Modified adenovirus or adeno-associated virus (AAV) vectors also 
were effective for gene delivery to the liver and the brain. They are restricted by the immune 
response to the adenovirus, and still limited in the tissues so as they can competently infect 
[192,193]. 
Recently, further therapeutic potentials for miRNAs clinical applications over stem cells 
signatures have been emerged. Particularly, in majority of malignant tumors, heterogeneous 
population of cells exist so as a proportion of which have been assigned the related stem 
cells. These cells are involved in tumorigenesis owing to their capability to self-renew and 
proliferation. At the same time, the ability of miRNAs to control many target genes gets 
them smart candidates for regulating stem cell self-renewal. Compelling evidence supports 
that specific miRNAs are differentially expressed in stem cells. It was showed that miRNAs 
are required to enable stem cells to overcome the G1-S checkpoint and achieve self-renewal. 
The exploitation of such miRNAs would smooth the progress of the regulation of the stem 
cells motivating tumorigenesis. An extra stem cell/miRNA therapeutic possibility is the use 
of mesenchymal stem cells as promising tumor-targeted vectors for miRNA therapeutics. Of 
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note, the advantages and challenges of miRNA-based therapeutics compared with 
conservative and routine treatments are needed taken into account comprehensively [194-
198]. The advantages involve regulation of many components of the same pathway/cellular 
via miRNA, stable and durable, and effective in vivo regulation of the miRNA. In contrast, 
the potential challenges include delivery of the miRNA modulator, off-target effects of 
unintended targets of a miRNA, toxicity of the miRNA modulator. It is important to keep in 
mind that a single miRNA can comprise both favorable and pathogenic effects. Besides, 
siRNA/miRNA specific delivery to target cell populations using approaches of 
nanobiotechnology is just beginning and looks promising. In a word, with the development 
in miRNA field, these small molecules are invaluable means for various areas of basic and 
applied research and, more importantly, for therapeutic intervention [199, 200]. 
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